Kiniksa Pharmaceuticals Ltd (KNSA) Expected to Post Earnings of -$0.50 Per Share

Equities research analysts expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to post earnings per share (EPS) of ($0.50) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.45). The business is expected to report its next quarterly earnings results on Monday, November 5th.

On average, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.71) to ($2.56). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.04) per share, with EPS estimates ranging from ($3.08) to ($2.99). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Monday, August 6th. The company reported ($0.97) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.53).

A number of brokerages have recently issued reports on KNSA. JMP Securities began coverage on Kiniksa Pharmaceuticals in a research note on Monday, June 18th. They set an “outperform” rating and a $33.00 price objective on the stock. Wedbush began coverage on Kiniksa Pharmaceuticals in a research note on Monday, June 18th. They set an “outperform” rating and a $31.00 price objective on the stock. JPMorgan Chase & Co. began coverage on Kiniksa Pharmaceuticals in a research note on Monday, June 18th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, Goldman Sachs Group began coverage on Kiniksa Pharmaceuticals in a research note on Monday, June 18th. They set a “neutral” rating on the stock.

Shares of Kiniksa Pharmaceuticals opened at $14.14 on Friday, Marketbeat reports. Kiniksa Pharmaceuticals has a 12-month low of $13.04 and a 12-month high of $24.64.

In other Kiniksa Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp bought 69,444 shares of the firm’s stock in a transaction that occurred on Tuesday, May 29th. The shares were acquired at an average cost of $18.00 per share, with a total value of $1,249,992.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider James E. Flynn bought 843,352 shares of the firm’s stock in a transaction that occurred on Tuesday, May 29th. The shares were acquired at an average cost of $18.97 per share, for a total transaction of $15,998,387.44. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 3,912,796 shares of company stock worth $71,248,379.

Several hedge funds have recently bought and sold shares of the stock. FMR LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $14,565,000. Vivo Capital LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $3,228,000. Victory Capital Management Inc. acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $2,461,000. Citadel Advisors LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $1,555,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $535,000. 0.42% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Story: Outstanding Shares

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply